Tau PET Longitudinal Substudy Associated With: A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-randomized, Placebo-treated Non-carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease

This substudy will evaluate the effect of crenezumab on the longitudinal tau burden in a subgroup of preclinical Presenilin1 (PSEN1) E280A mutation carriers and non-carriers, who were enrolled in study NCT01998841 (GN28352). Participants will receive up to three intravenous (IV) injections of [^18F] Genentech Tau Probe 1 (GTP1) and will undergo a tau positron emission tomography (PET) scan after each IV injection of [18^F]GTP1. The purpose of this substudy is to increase the understanding of disease progression in the preclinical stage of familial Alzheimer's Disease (AD).

Start Date10 Jun 2019

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

[+2]

CTR20180392 / SuspendedPhase 3

在前驱期至轻度阿尔茨海默病患者中评价CRENEZUMAB有效性和安全性的III期、多中心、随机、双盲、安慰剂对照、平行研究

[Translation] A Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of CRENEZUMAB in patients with prodromal to mild Alzheimer's disease

本研究的目的是评价Crenezumab对比安慰剂在前驱期至轻度阿尔茨海默病（AD）患者中的疗效、安全性和药代动力学。

[Translation]

The purpose of this study was to evaluate the efficacy, safety, and pharmacokinetics of crenezumab versus placebo in patients with prodromal to mild Alzheimer's disease (AD).

Start Date28 May 2018

Sponsor / Collaborator

F. Hoffmann-La Roche Ltd.

[+2]

NCT03491150 / TerminatedPhase 3

A Multicenter, Open-Label, Long-Term Extension Of Phase III Studies (BN29552/BN29553) Of Crenezumab In Patients With Alzheimer's Disease

In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg intravenous (IV) every 4 weeks (Q4W) will be offered to all participants who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate safety in participants on long-term crenezumab treatment and to investigate the effect of crenezumab on the underlying disease process and disease course as an exploratory efficacy objective.

Start Date11 Apr 2018

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

100 Clinical Results associated with Crenezumab

100 Translational Medicine associated with Crenezumab

100 Patents (Medical) associated with Crenezumab

250

Literatures (Medical) associated with Crenezumab

01 Sep 2024·Clinical pharmacology and therapeutics

Evaluation of Patient‐Centric Sample Collection Technologies for Pharmacokinetic Assessment of Large and Small Molecules

Article

Author: Simon, Mary ; Yang, Xiaoyun ; Chen, Liuxi ; Fischer, Saloumeh ; Johnson, Ryan ; Zou, Yixuan ; Sutaria, Dhruvitkumar S ; Williams, Kathi ; Dean, Brian ; Cardenas, Alison ; Sane, Rucha ; Mandlekar, Sandhya

Low‐volume sampling devices offer the promise of lower discomfort and greater convenience for patients, potentially reducing patient burden and enabling decentralized clinical trials. In this study, we determined whether low‐volume sampling devices produce pharmacokinetic (PK) data comparable to conventional venipuncture for a diverse set of monoclonal antibodies (mAbs) and small molecules. We adopted an open‐label, non‐randomized, parallel‐group, single‐site study design, with four cohorts of 10 healthy subjects per arm. The study drugs, doses, and routes of administration included: crenezumab (15 mg/kg, intravenous infusion), etrolizumab (210 mg, subcutaneous), GDC‐X (oral), and hydroxychloroquine (HCQ, 200 mg, oral). Samples were collected after administration of a single dose of each drug using conventional venipuncture and three low‐volume capillary devices: TassoOne Plus for liquid blood, Tasso‐M20 for dry blood, both applied to the arm, and Neoteryx Mitra® for dry blood obtained from fingertips. Serum/plasma concentrations from venipuncture and TassoOne Plus samples overlapped and PK parameters were comparable for all drugs, except HCQ. After applying a baseline hematocrit value, the dry blood concentrations and PK parameters for the two monoclonal antibodies were comparable to those obtained from venipuncture. For the two small molecules, two bridging strategies were evaluated for converting dry blood concentrations to equivalent plasma concentrations. A baseline hematocrit correction and/or linear regression‐based correction was effective for GDC‐X, but not for HCQ. Additionally, the study evaluated the bioanalytical data quality and comparability from the various collection methods, as well as patient preference for the devices.

01 Jun 2024·PROTEIN SCIENCE

Native ion mobility‐mass spectrometry reveals the binding mechanisms of anti‐amyloid therapeutic antibodies

Article

Author: Zupancic, Jennifer M ; Smith, Matthew D ; Ruotolo, Brandon T ; Tessier, Peter M ; Han, Yilin ; Desai, Alec A

Abstract:

One of the most important attributes of anti‐amyloid antibodies is their selective binding to oligomeric and amyloid aggregates. However, current methods of examining the binding specificities of anti‐amyloid β (Aβ) antibodies have limited ability to differentiate between complexes that form between antibodies and monomeric or oligomeric Aβ species during the dynamic Aβ aggregation process. Here, we present a high‐resolution native ion‐mobility mass spectrometry (nIM‐MS) method to investigate complexes formed between a variety of Aβ oligomers and three Aβ‐specific IgGs, namely two antibodies with relatively high conformational specificity (aducanumab and A34) and one antibody with low conformational specificity (crenezumab). We found that crenezumab primarily binds Aβ monomers, while aducanumab preferentially binds Aβ monomers and dimers and A34 preferentially binds Aβ dimers, trimers, and tetrameters. Through collision induced unfolding (CIU) analysis, our data indicate that antibody stability is increased upon Aβ binding and, surprisingly, this stabilization involves the Fc region. Together, we conclude that nIM‐MS and CIU enable the identification of Aβ antibody binding stoichiometries and provide important details regarding antibody binding mechanisms.

01 Jun 2024·Acta neuropathologica

Correction: Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncted Abeta in sporadic Alzheimer disease cases and mouse models

Author: Parker, Michael W ; Bayer, Thomas A ; Tucholla, Petra ; Wiltfang, Jens ; Crespi, Gabriela A N ; Noguerola, Jose Socrates Lopez ; Miles, Luke A ; Bouter, Yvonne

News (Medical) associated with Crenezumab

25 Sep 2024

·www.globenewswire.com

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the e-poster presentation of a post hoc analysis of the SHINE Phase 2b study of its first-in-class anti-C5a antibody, vilobelimab, in hidradenitis suppurativa (HS) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress being held in Amsterdam, September 25 – 28, 2024. Camilla Chong, MD, Chief Medical Officer of InflaRx, commented: “This analysis sheds significant light on the role of C5a/C5aR signaling and vilobelimab’s ability to address the underlying inflammation driving hidradenitis suppurativa (HS), including its potential to reduce not only abscesses and nodules, but draining tunnels that remain a significant burden for many patients with this debilitating disease. In addition, we believe exploring additional efficacy parameters for HS in addition to HiSCR (Hidradenitis Suppurativa Clinical Response) could lead to a greater understanding of the disease-modifying potential of C5a inhibitors such as vilobelimab and C5aR inhibitors such as INF904, particularly with regard to reducing draining tunnels.” E-poster: P0063 Vilobelimab demonstrates significant improvement in reduction of draining tunnels, total lesion count, International Hidradenitis Suppurativa Score 4 and the newly introduced modified-HiSCR: a post hoc analysis of the Phase IIb SHINE study Authors Evangelos J. Giamarellos-Bourboulis, Christopher Sayed, Jamie Weisman, Jacek Szepietowski, Falk Bechara, Niels C. Riedemann, Camilla Chong, Hoda Tawfik SHINE was a prospective, randomized, placebo-controlled, double-blind multicenter Phase 2b trial in 177 patients with moderate to severe HS, with results announced in 2019. The post hoc analysis presented at EADV 2024 looked at other important clinical efficacy endpoints and, in particular vilobelimab 1200 mg, which was statistically significant compared to placebo at 16 weeks. Efficacy parameters assessed included the reduction of draining tunnels (dT), reduction of total lesion counts (abscesses + nodules + draining tunnels (ANdT)) and the International Hidradenitis Suppurativa Score 4 (IHS4) compared to placebo. In this post hoc analysis, vilobelimab 1200 mg demonstrated a placebo-adjusted significant reduction in dT, ANdT, and IHS4 of 45.2%, 25.1% and 31.6%, respectively. InflaRx believes this analysis suggests meaningful clinical benefit for vilobelimab in HS. Further, it supports utilizing a modified version of the HiSCR that measures drug activity against all three lesion types with an emphasis on the reduction of dT, a critical manifestation of the disease that greatly impacts patients’ quality of life. About GOHIBIC (vilobelimab) Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, vilobelimab leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism of the innate immune system, which is not the case for molecules blocking C5. In pre-clinical studies, vilobelimab has been shown to control the inflammatory response-driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response. In addition to development in COVID-19, vilobelimab is also being developed for various debilitating or life-threatening inflammatory indications, including pyoderma gangrenosum (PG). In April 2023, the FDA issued the EUA for GOHIBIC (vilobelimab) for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). In January 2024, InflaRx announced the launch of The InflaRx Commitment Program, pursuant to which the cost of GOHIBIC (vilobelimab) will be refunded for up to six (6) administered inpatient doses (the full treatment course) to institutions that meet the eligibility requirements, for patients who were administered GOHIBIC (vilobelimab) in line with its EUA and who died due to COVID-19 in the intensive care unit. The Marketing Authorization Application (MAA) for the treatment of adult patients with SARS-CoV-2 induced septic ARDS receiving IMV or ECMO is under regulatory review by the European Committee for Medicinal Products for Human Use under the centralized procedure, which applies to all 27 member states of the European Union. About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx). Contacts: InflaRx N.V.MC Services AGJan Medina, CFAVice President, Head of Investor RelationsEmail: IR@inflarx.deKatja Arnold, Laurie Doyle, Dr. Regina LutzEmail: inflarx@mc-services.eu Europe: +49 89-210 2280U.S.: +1-339-832-0752 FORWARD-LOOKING STATEMENTSThis press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

Clinical ResultPhase 2Drug Approval

31 Jul 2024

·www.fiercebiotech.com

AC Immune claims new class of Alzheimer's-focused ADC has 'landmark' CNS potential

Understanding the mechanism of morADCs, and whether the drugs are able to reach plaques that build up inside of neurons, too, remain key questions before moving into the clinic. After more than two decades of work on neurodegenerative diseases, Swiss biotech AC Immune claims it could have a game changer on its hands.The company’s chief scientific officer, Madiha Derouazi, Ph.D., presented preclinical results from its brain-penetrant small molecule Morphomer platform at the Alzheimer’s Association International Conference on July 29. The idea is to combine these Morphomers with monoclonal antibodies from its SupraAntigen liposome platform to create a new class of neurodegenerative disease-fighting drug candidates called Morphomer antibody-drug conjugates (morADCs).AC Immune hopes that these morADCs can target misfolded proteins, like amyloid beta and tau, which form the characteristic plaques and tangles in the brains of Alzheimer’s patients. The flexibility of the morADC model means they can even have a dual-targeting strategy—for example, by pairing an anti-amyloid beta antibody with an anti-tau small molecule.It's a different setting for ADCs, which have made their name in oncology by homing in on specific tumor cells to kill.The biotech has already conducted preclinical tests, which showed that morADCs penetrated the blood-brain barrier of mice at a rate three to six times higher than its monoclonal antibody alone. “Somehow the small molecule helps to deliver the antibody to the brain,” AC Immune co-founder and CEO Andrea Pfeifer, Ph.D., told Fierce Biotech in an interview. “That was a totally unexpected result.” Alzheimer’s therapeutics have primarily targeted amyloid beta, with mixed results. The first approved drug in this class, Biogen’s Aduhelm, is being discontinued by the biotech in favor of the newer Leqembi, which itself was recently spurned by the European Medicines Agency over safety concerns. Eli Lilly’s Kisunla was approved by the FDA earlier this month but has also attracted criticism for its modest benefits compared to the risk of serious side effects.Pfeifer is supportive of these anti-amyloid drugs. “I'm almost now defending other people's programs, which is unusual,” she said. “I do believe that the [Leqembi] and [Kisunla] approval in America is a great thing for the community,” the CEO added. But while targeting amyloid beta works for the early stages of Alzheimer’s, “very soon you need [to target] tau.”Using morADCs, AC Immune was able to target both amyloid beta and tau, with the small molecule component binding to and deactivating the misfolded proteins. Pfeifer was surprised to find that the drug showed greater activity than the sum of its constituent parts, the monoclonal antibody and small molecule. “It's not that one and one makes two, it's one and one makes maybe five,” Pfeifer said. The two parts of a morADC “both work together and can be against one target or two targets, but the effect together is a synergistic effect.”How exactly morADCs work remains a mystery. “I can imagine this becomes now the prime focus for AC Immune, because it's an enormous opportunity,” Pfeifer said. “Nobody else has it.” A promising asset like morADCs is likely welcome news for AC Immune after its monoclonal antibody crenezumab failed in a clinical trial of early-onset Alzheimer’s patients in 2022. Not that the biotech let that disappointment slow it down for long—the company sold an option to a phase 2 anti-amyloid beta active immunity drug to Takeda for $100 million upfront in May of this year.Understanding the mechanism of morADCs, and whether the drugs are able to reach plaques that build up inside of neurons, too, remain key questions before moving into the clinic, which Pfeifer expects will take some time.“I think we are a few years away from the clinic, but potential is pretty high,” she said. “It could be a landmark change in CNS.”

Drug ApprovalImmunotherapyPhase 2ADC

16 Jul 2024

·www.globenewswire.com

AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024

AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060, and ACI-19626 Lausanne, Switzerland, July 16, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced three oral presentations highlighting its precision medicine pipeline at the annual Alzheimer’s Association International Conference (AAIC 2024), taking place in Philadelphia, PA, on July 28 - August 1, 2024. Presentation details (all times are EDT) Discovery and preclinical development of [18F]ACI-19626, a first-in-class TDP-43-PET tracer Date: Monday, July 29, 2024 | 2:50 PM – 3:00 PMLocation: Hall A - Pennsylvania Convention Center Presenter: Tamara Seredenina, PhD (AC Immune) Active immunotherapy, ACI-24.060, induces anti-Abeta antibodies with binding profiles mirroring clinically validated monoclonal antibodies Date: Tuesday, July 30, 2024 | 9:40 AM – 9:50 PMLocation: 201 ABC - Pennsylvania Convention CenterPresenter: Emma Fiorini, PhD (AC Immune) A new class of neurodegenerative disease-fighting drugs: morADC (Morphomer®- Antibody Drug Conjugates)Date: Wednesday, July 31, 2024 | 8:07 AM – 8:14 AMLocation: 118 ABC - Pennsylvania Convention Center Presenter: Madiha Derouazi, PhD (AC Immune) Poster details#18 Comparative analysis of clinical endpoint progression rates in sporadic Alzheimer’s disease and Down Syndrome-related Alzheimer’s diseaseDate: Tuesday, July 30, 2024 | 8:00 AM – 4:15 PMLocation: Exhibit Hall - Pennsylvania Convention CenterPresenter: Michael Rafii, MD, PhD (Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA) About AC Immune SAAC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding in potential milestone payments plus royalties. SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU. The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release. For further information, please contact: Head of Investor Relations & Corporate CommunicationsGary Waanders, Ph.D., MBAAC ImmunePhone: +41 21 345 91 91Email: gary.waanders@acimmune.comU.S. InvestorsCorey Davis, Ph.D.LifeSci AdvisorsPhone: +1 212 915 2577 Email: cdavis@lifesciadvisors.comInternational MediaChris MaggosCohesion BureauPhone: +41 79 367 6254Email: chris.maggos@cohesionbureau.com Forward looking statementsThis press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward- looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement. Attachment 20240716_ACIU_AAIC-curtain raiser-CLEAN

ImmunotherapyPhase 2Phase 3

100 Deals associated with Crenezumab

External Link

KEGG	Wiki	ATC	Drug Bank
D10101	Crenezumab	-	DB11959

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	US	Hoffmann-La Roche, Inc.	22 Mar 2016
Alzheimer Disease	Phase 3	JP	Hoffmann-La Roche, Inc.	22 Mar 2016
Alzheimer Disease	Phase 3	AU	Hoffmann-La Roche, Inc.	22 Mar 2016
Alzheimer Disease	Phase 3	AT	Hoffmann-La Roche, Inc.	22 Mar 2016
Alzheimer Disease	Phase 3	BE	Hoffmann-La Roche, Inc.	22 Mar 2016
Alzheimer Disease	Phase 3	BG	Hoffmann-La Roche, Inc.	22 Mar 2016
Alzheimer Disease	Phase 3	CA	Hoffmann-La Roche, Inc.	22 Mar 2016
Alzheimer Disease	Phase 3	CR	Hoffmann-La Roche, Inc.	22 Mar 2016
Alzheimer Disease	Phase 3	HR	Hoffmann-La Roche, Inc.	22 Mar 2016
Alzheimer Disease	Phase 3	CZ	Hoffmann-La Roche, Inc.	22 Mar 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03977584 (CTgov)	Phase 2	Alzheimer Disease	114	Crenezumab (Crenezumab - Mutation Carriers)	dgnshxouem(cekwhipyqs) = yneqphosjb bsvrpylibs (hrhdsymkaa, xxiytlmikv - bimgbbbopp) View more	-	15 Mar 2024
				placebo+crenezumab+[^18F]GTP1 (Placebo - Mutation Carriers)	dgnshxouem(cekwhipyqs) = nvjhrsmcwu bsvrpylibs (hrhdsymkaa, wohqdjwynl - trbirbsihf)
NCT02670083 (CREAD, Pubmed) Manual	Phase 3	Alzheimer Disease	813	Crenezumab	bjjhidyfji(tnkksnnwnx) = epebqfvfqm jkydoqyuze (dsdkiuwdry, 3.07 - 4.11) View more	Negative	19 Sep 2022
				Placebo	bjjhidyfji(tnkksnnwnx) = txfhhgtarl jkydoqyuze (dsdkiuwdry, 2.90 - 3.93) View more
NCT01998841 (API ADAD, Corporate Publications) Manual	Phase 2	Alzheimer Disease	252	Crenezumab	qcvyepivuw(smsmoxiwar) = mwzwbwkxuy sywpgahksj (bycfayfvgk ) View more	Negative	02 Aug 2022
				Placebo	-
NCT02670083 (CREAD, CTgov)	Phase 3	Alzheimer Disease	813	Placebo (Placebo)	urpczpxnzc(igmwphuzsg) = ybfbtkryqa ddhwmhlsrw (ozefegsohh, rhgskkckfu - aanekjehnw) View more	-	16 Jul 2020
				Crenezumab (Crenezumab)	urpczpxnzc(igmwphuzsg) = ngmcbjwokr ddhwmhlsrw (ozefegsohh, jfjrjnkgan - nkctvrgnti) View more
NCT03114657 (CREAD2 \| CREAD 2, CTgov)	Phase 3	Alzheimer Disease	806	Placebo (Placebo)	xsqsmwrjdp(arvzoavrng) = hwrymygrzd pzolaseasq (nvexalbwbu, ciycjbjbrp - dswfgqmvuf) View more	-	16 Jul 2020
				Crenezumab (Crenezumab)	xsqsmwrjdp(arvzoavrng) = vclmwcgiyr pzolaseasq (nvexalbwbu, xyvgpoxuwk - vjkhfgvbmo) View more
NCT03491150 (CREAD OLE, CTgov)	Phase 3	Alzheimer Disease	149	Crenezumab (Parent Placebo)	qtvkythyhd(nnneagkptw) = oqhbqiaove zmvblvmagh (keydechkwm, wacpitblui - jqfrnyvnfm) View more	-	09 Jun 2020
				Crenezumab (Parent Crenezumab)	qtvkythyhd(nnneagkptw) = qntkygxite zmvblvmagh (keydechkwm, uruqlujeio - kasrvhtujb) View more
NCT02353598 (GlobeNewswire) Manual	Phase 1	Alzheimer Disease	52	crenezumab	uyobelptwf(rwjuouscku) = mjyseaazvl cswcykfrdu (vuvzgtensn ) View more	Positive	09 Dec 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis